Monte Rosa Therapeutics (GLUE) Profit After Tax (2020 - 2026)

Monte Rosa Therapeutics' Profit After Tax history runs 7 years deep, the most recent figure standing at -$45.4 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 196.82% year-over-year to -$45.4 million; the TTM figure through Mar 2026 stood at -$130.9 million (down 2643.86% YoY), while the FY2025 annual figure was -$38.6 million, up 47.36% from the prior year.
• Profit After Tax for Q1 2026 stood at -$45.4 million, up from -$46.1 million in the prior quarter.
• The five-year high for Profit After Tax was $46.9 million in Q1 2025, with the low at -$46.1 million in Q4 2025.
• The 5-year median for Profit After Tax is -$30.2 million (2022), against an average of -$23.6 million.
• Peak annual rise in Profit After Tax reached 246.75% in 2025, while the deepest fall reached 471.76% in 2025.
• Monte Rosa Therapeutics' Profit After Tax stood at -$30.2 million in 2022, then declined by 11.25% to -$33.6 million in 2023, then jumped by 136.92% to $12.4 million in 2024, then plunged by 471.76% to -$46.1 million in 2025, then grew by 1.49% to -$45.4 million in 2026.
• Business Quant data shows GLUE's Profit After Tax at -$45.4 million in Q1 2026, -$46.1 million in Q4 2025, and -$27.1 million in Q3 2025.